IN2014CN03647A - - Google Patents
Info
- Publication number
- IN2014CN03647A IN2014CN03647A IN3647CHN2014A IN2014CN03647A IN 2014CN03647 A IN2014CN03647 A IN 2014CN03647A IN 3647CHN2014 A IN3647CHN2014 A IN 3647CHN2014A IN 2014CN03647 A IN2014CN03647 A IN 2014CN03647A
- Authority
- IN
- India
- Prior art keywords
- dysfunctions
- psychotic
- alpha
- provides methods
- subject suffering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161549319P | 2011-10-20 | 2011-10-20 | |
PCT/IB2012/055692 WO2013057687A2 (en) | 2011-10-20 | 2012-10-18 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN03647A true IN2014CN03647A (lt) | 2015-10-09 |
Family
ID=47297333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3647CHN2014 IN2014CN03647A (lt) | 2011-10-20 | 2012-10-18 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2768507B1 (lt) |
JP (1) | JP6162705B2 (lt) |
KR (1) | KR102043077B1 (lt) |
CN (1) | CN103930112B (lt) |
AU (1) | AU2012324458B2 (lt) |
BR (1) | BR112014007485B1 (lt) |
CA (2) | CA2852268C (lt) |
EA (1) | EA034964B1 (lt) |
ES (1) | ES2776996T3 (lt) |
IN (1) | IN2014CN03647A (lt) |
JO (1) | JO3766B1 (lt) |
MX (1) | MX2014004621A (lt) |
TW (1) | TWI635861B (lt) |
WO (1) | WO2013057687A2 (lt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN111956803A (zh) | 2014-10-20 | 2020-11-20 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
KR102485299B1 (ko) | 2016-04-07 | 2023-01-06 | 오이스터 포인트 파마 인코포레이티드 | 안구 장애의 치료 방법 |
US11433057B2 (en) * | 2016-05-20 | 2022-09-06 | Vanda Pharmaceuticals Inc. | Method for improving or enhancing cognition |
CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
JP2022538955A (ja) | 2019-03-19 | 2022-09-07 | ケンブリッジ コグニション リミテッド | 精神障害のための治療の診断および推奨の方法および利用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
CA2153387A1 (en) | 1993-01-07 | 1994-07-21 | Hubert Koester | Dna sequencing by mass spectrometry |
US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
US20010049586A1 (en) | 2000-04-05 | 2001-12-06 | Roses Allen David | Iterative analysis of non-responding population in the design of pharmacogenetic studies |
GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
JP4890762B2 (ja) | 2002-09-25 | 2012-03-07 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、及びベンゾイソチアゾール、並びにそれらの調製及び使用 |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
AU2004325725A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
MX2008014672A (es) | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
WO2009066107A1 (en) | 2007-11-21 | 2009-05-28 | Astrazeneca Ab | Use of a nicotinic receptor agonist |
MX2011003429A (es) | 2008-10-13 | 2011-05-02 | Hoffmann La Roche | Metodo libre de diazonio para fabricar un compuesto intermedio de indazol en la sintesis de las amidas del acido 5-(trifluorometoxi)-1h-3-indazolcarboxilico biciclico. |
CN102209540A (zh) | 2008-11-11 | 2011-10-05 | 塔加西普特公司 | 使用α7-选择性配体的治疗方法 |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
JO3250B1 (ar) * | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
-
2012
- 2012-10-18 BR BR112014007485-2A patent/BR112014007485B1/pt active IP Right Grant
- 2012-10-18 AU AU2012324458A patent/AU2012324458B2/en active Active
- 2012-10-18 IN IN3647CHN2014 patent/IN2014CN03647A/en unknown
- 2012-10-18 MX MX2014004621A patent/MX2014004621A/es active IP Right Grant
- 2012-10-18 WO PCT/IB2012/055692 patent/WO2013057687A2/en active Application Filing
- 2012-10-18 CN CN201280051452.1A patent/CN103930112B/zh active Active
- 2012-10-18 KR KR1020147010115A patent/KR102043077B1/ko active IP Right Grant
- 2012-10-18 JP JP2014536391A patent/JP6162705B2/ja active Active
- 2012-10-18 EA EA201490832A patent/EA034964B1/ru unknown
- 2012-10-18 JO JOP/2012/0311A patent/JO3766B1/ar active
- 2012-10-18 ES ES12797979T patent/ES2776996T3/es active Active
- 2012-10-18 EP EP12797979.7A patent/EP2768507B1/en active Active
- 2012-10-18 CA CA2852268A patent/CA2852268C/en active Active
- 2012-10-18 CA CA3083244A patent/CA3083244C/en active Active
- 2012-10-19 TW TW101138792A patent/TWI635861B/zh active
Also Published As
Publication number | Publication date |
---|---|
JP2015501306A (ja) | 2015-01-15 |
JP6162705B2 (ja) | 2017-07-12 |
BR112014007485B1 (pt) | 2022-05-31 |
TW201322980A (zh) | 2013-06-16 |
WO2013057687A2 (en) | 2013-04-25 |
KR20140081822A (ko) | 2014-07-01 |
CA3083244C (en) | 2023-01-03 |
AU2012324458B2 (en) | 2016-05-19 |
TWI635861B (zh) | 2018-09-21 |
ES2776996T3 (es) | 2020-08-03 |
EP2768507A2 (en) | 2014-08-27 |
CA2852268C (en) | 2020-08-25 |
KR102043077B1 (ko) | 2019-11-11 |
CN103930112A (zh) | 2014-07-16 |
BR112014007485A2 (pt) | 2017-04-04 |
MX2014004621A (es) | 2014-08-22 |
EA201490832A1 (ru) | 2015-12-30 |
AU2012324458A1 (en) | 2014-05-01 |
EA034964B1 (ru) | 2020-04-13 |
CN103930112B (zh) | 2018-11-09 |
JO3766B1 (ar) | 2021-01-31 |
CA2852268A1 (en) | 2013-04-25 |
CA3083244A1 (en) | 2013-04-25 |
EP2768507B1 (en) | 2019-12-11 |
WO2013057687A3 (en) | 2013-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN03647A (lt) | ||
JO3715B1 (ar) | منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني | |
PH12014500995A1 (en) | Pak inhibitors for the treatment of cell proliferative disorders | |
HK1254745A1 (zh) | Gpr119受體調節劑和對與其相關的障礙的治療 | |
MX355543B (es) | Macrociclos peptidomiméticos. | |
JO3131B1 (ar) | مركبات كيميائية | |
MX353143B (es) | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. | |
HK1199030A1 (zh) | 用於治療 受體相關疾病的取代的 -苯基吡啶 | |
EP2817068A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEUROGENIC DISEASES OF THE POOL FLOOR | |
TW200745109A (en) | Pyrrolo-pyridine kinase modulators | |
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
IN2014DN00288A (lt) | ||
IN2014DN00286A (lt) | ||
IN2014MN00093A (lt) | ||
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
WO2008124849A3 (en) | Pyrrolo-pyridine kinase modulators | |
GB201103062D0 (en) | Method | |
IN2012DN02485A (lt) | ||
IN2014MN01378A (lt) | ||
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
IL232334A0 (en) | Modulators of the G protein-coupled mas receptor and the treatment of related disorders | |
EP2605655A4 (en) | METHOD FOR TREATING EASY COGNITIVE IMPAIRMENT (MCI) AND RELATED DISEASES | |
EP3110974A4 (en) | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders | |
WO2012173846A3 (en) | Peptidomimetic macrocycles | |
SG11201406192VA (en) | Method for assessing the treatment of attention-deficit/hyperactivity disorder |